Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639637 · ClinicalTrials.gov registry record · Phase 4
Effect of DPP4 Inhibition on Vasoconstriction
A Phase 4 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT02639637 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 18 participants.
The verdict
NCT02639637, a Phase 4 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an endogenous peptide. The central hypothesis is that DPP4 inhibition decreases degradation of neuropeptide Y, resulting in increased vasoconstriction and sympathetic activation.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Neuropeptide Y
- DRUG Valsartan 160mg
- DRUG Enalaprilat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02639637
The ClinicalTrials.gov registry entry for NCT02639637 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02639637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02639637 about?
NCT02639637 is a clinical study titled "Effect of DPP4 Inhibition on Vasoconstriction". The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an endogenous peptide. The central hypothesis is that DPP4 inhibition decreas...
What is the current status of trial NCT02639637?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2015-12. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02639637?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Neuropeptide Y (DRUG), Valsartan 160mg (DRUG), Enalaprilat (DRUG).
Who is sponsoring clinical trial NCT02639637?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.